Corporate 19 March 2025 7 mins read

Ipsen announces issuance of €500 million inaugural Rated Public Bond

Regulated Information 06 March 2025 1 mins read

Ipsen – February 2025 – Monthly information relative to the total number of voting rights and shares composing the share capital

Regulated Information 21 February 2025 1 mins read

Ipsen S.A. publishes its 2024 consolidated financial statements

Regulated Information 06 February 2025 1 mins read

Ipsen – January 2025 – Monthly information relative to the total number of voting rights and shares composing the share capital

Regulated Information 07 January 2025 1 mins read

Ipsen – Half year statement – 2024 12 31

Regulated Information 07 January 2025 1 mins read

Ipsen – December 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital

Regulated Information 09 December 2024 1 mins read

Ipsen – November 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital

Regulated Information 07 November 2024 1 mins read

Ipsen – October 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital

Regulated Information 09 October 2024 1 mins read

Ipsen – September 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital

Corporate 18 September 2024 9 mins read

Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors